Selumetinib, Differentiated Thyroid Cancer , AZD6244
Showing 1 - 25 of >10,000
Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological
Completed
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Laboratory Biomarker Analysis
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Sep 14, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston
Recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Portland (procedure, drug,
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Biopsy
- +6 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 29, 2022
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)
Active, not recruiting
- Malignant Peripheral Nerve Sheath Tumors
- Neurofibromatosis 1
-
Washington, District of Columbia
- +4 more
Apr 1, 2022
NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Boston, Massachusetts
- +3 more
Aug 1, 2022
Malignant Tumor of Breast, Malignant Tumors of Digestive Organs, Malignant Tumors of Female Genital Organs Trial in Houston
Recruiting
- Malignant Neoplasm of Breast
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 29, 2021
Cancer, Non Small Cell Lung Cancer Trial in United Kingdom (Vandetanib, Selumetinib)
Completed
- Cancer
- Non Small Cell Lung Cancer
- Vandetanib, Selumetinib
-
Headington, Oxford, United Kingdom
- +3 more
Sep 9, 2021
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV Trial in Worldwide (Selumetinib 75 mg, Docetaxel 75
Completed
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Selumetinib 75 mg
- +3 more
-
Santa Monica, California
- +50 more
Nov 22, 2022
Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma Trial in Canada, United States
Recruiting
- Recurrent Low Grade Astrocytoma
- +4 more
- Quality-of-Life Assessment
- +3 more
-
Birmingham, Alabama
- +64 more
Aug 20, 2022
Biliary Tract Carcinoma, Gallbladder Carcinoma Trial in Toronto (Selumetinib, Cisplatin, Gemcitabine)
Active, not recruiting
- Biliary Tract Carcinoma
- Gallbladder Carcinoma
- Selumetinib
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 14, 2021
KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7 Trial in United
Completed
- KRAS NP_004976.2:p.G12R
- +2 more
- Laboratory Biomarker Analysis
- Selumetinib Sulfate
-
Los Angeles, California
- +8 more
Jan 20, 2021
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric Trial in Denmark,
Recruiting
- Acute Lymphoblastic Leukemia
- +4 more
-
Copenhagen, Denmark
- +16 more
Jan 26, 2022
Breast Cancer Trial in Houston (Dasatinib, AZD6244)
Terminated
- Breast Cancer
-
Houston, TexasUT MD Anderson Cancer Center
Sep 1, 2020
Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland
Completed
- Refractory Differentiated Thyroid Gland Carcinoma
- +4 more
- Cediranib
- +3 more
-
Duarte, California
- +32 more
Jun 24, 2021
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer Trial in San Francisco, Columbus
Completed
- Adenocarcinoma of the Pancreas
- +3 more
- erlotinib hydrochloride
- +2 more
-
San Francisco, California
- +1 more
Jul 29, 2020
Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma Trial in United States
Completed
- Borderline Ovarian Serous Tumor
- +5 more
- Laboratory Biomarker Analysis
- +3 more
-
Los Angeles, California
- +48 more
Dec 2, 2020
NSCLC, Carcinoma, Squamous Cell, Adenocarcinoma Trial in United Kingdom (AZD4547, Vistusertib, Palbociclib)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +2 more
- AZD4547
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Nov 2, 2021
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV Trial in Worldwide (Selumetinib, Docetaxel, Placebo)
Active, not recruiting
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Selumetinib
- +3 more
-
Aurora, Colorado
- +196 more
Dec 22, 2022
Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma Trial (Biopsy, Biospecimen Collection, Bone Marrow Aspiration and
Not yet recruiting
- Recurrent Endometrial Carcinoma
- Recurrent Ovarian Carcinoma
- Biopsy
- +5 more
- (no location specified)
Sep 29, 2022
Non-Metastatic Adenocarcinoma of the Rectum Trial run by the NCI (Radiation Therapy, Capecitabine, AZD6244)
Terminated
- Non-Metastatic Adenocarcinoma of the Rectum
- Radiation Therapy
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 1, 2021
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)
Active, not recruiting
- Neurofibromatosis 1
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Neurofibromatosis 1, Plexiform Neurofibroma (PN) Trial in Worldwide (Selumetinib, Placebo)
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibroma (PN)
- Selumetinib
- Placebo
-
Gainesville, Florida
- +40 more
Jan 16, 2023